Biogen Message Board - Msg: 11558608

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen

BIIB 176.33

+0.9%

Dec 24 12:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: michael modeme who wrote (1142)	10/15/1999 8:43:00 AM
From: Harold Engstrom	Read Replies (4) of 1686

It appears that Teva and Hoechst paid for the study: * Biogen (NasdaqNM:BGEN - news) rivals funded a researcher who issued a study critical of the firm's Avonex drug. The researcher said he received a grant from a joint venture of Teva P (NasdaqNM:TEVA - news) pharmaceuticals and a Hoechst (quote from Yahoo! UK & Ireland: HOEG.F) unit. This is pretty much standard fare from Teva.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next